Skip directly to content

INFLECTRA (infliksimab)

*CT-P13 was designed with comparable efficacy, safety and quality to reference infliximab, to increase the treatment options for your Crohn’s disease and ulcerative colitis patients.6,8 Increasing real-world experience confirms the CT-P13 clinical efficacy and safety profile.9

†CT-P13 is marketed under different brand names including INFLECTRA® (infliximab) and REMSIMA™(infliximab).

CD, Crohn’s disease; ECCO, European Crohn’s and Colitis Organisation; IBD, Inflammatory bowel disease; UC, Ulcerative colitis.


Viited: 1. Gecse KB, et al. J Crohns Colitis 2016;10(2):133-40. 2. Jørgensen KK, et al. Lancet 2017;389:2304-16. 3. QuintilesIMS. MIDAS, February 2017. 4. INFLECTRA® (infliximabum) ravimi omaduste kokkuvõte 09/2018. 5. Araujo FC, et al. Curr Rheumatol Rep 2016;18:50. 6. European Public Assessment Report: INFLECTRA™. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed December 2017. 7. Yoo DH. Expert Rev Clin Immunol 2017;13(7):653-6. 8. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2012/06/WC500128686.pdf. Accessed December 2017. 9. Danese S, et al. J Crohns Colitis 2017;11:26-34.